A Computational Approach for Identifying Synergistic Drug Combinations

Treatment of Vemurafenib-Resistant SKMEL-28 Melanoma Cells with Paclitaxel

(2015) Dinh Thang Nguyen et al.   Asian Pacific Journal of Cancer Prevention

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

(2015) Adam A. Friedman et al.   PLoS One

A community computational challenge to predict the activity of pairs of compounds

(2014) Mukesh Bansal et al.   NATURE BIOTECHNOLOGY

Calculated treatment

(2013) Natalia L. Komarova et al.   NATURE

Maximum-Tolerated Dose, Optimum Biologic Dose, or Optimum Clinical Value: Dosing Determination of Cancer Therapies

(2012) John L. Marshall   JOURNAL OF CLINICAL ONCOLOGY

Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening

(2012) Matthew A. Held et al.   Cancer Discovery

Systematic exploration of synergistic drug pairs

(2011) M. Cokol et al.   Molecular Systems Biology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma

(2011) Annette Pflugfelder et al.   PLoS One

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Drug interactions and the evolution of antibiotic resistance

(2009) Pamela J. Yeh et al.   NATURE REVIEWS MICROBIOLOGY